Rituximab as third-line treatment for refractory or recurrent Stage III or IV follicular non-Hodgkin's lymphoma: a systematic review and economic evaluation

• B. Wake,
• C. Hyde,
• S. Bryan,
• P. Barton,
• F. Song,
• A. Fry-Smith,
• C. Davenport

Affiliations

B. Wake

Department of Public Health and Epidemiology, University of Birmingham, UK

C. Hyde

Department of Public Health and Epidemiology, University of Birmingham, UK

S. Bryan

Health Economics Facility, Health Services Management Centre, University of Birmingham, UK

P. Barton

Health Economics Facility, Health Services Management Centre, University of Birmingham, UK

F. Song

Department of Public Health and Epidemiology, University of Birmingham, UK

A. Fry-Smith

Department of Public Health and Epidemiology, University of Birmingham, UK

C. Davenport

Department of Public Health and Epidemiology, University of Birmingham, UK